Philips, established in 1891 and headquartered in Amsterdam, Netherlands, is a global leader in health technology, committed to improving people's health and well-being through meaningful innovation. The company's portfolio includes diagnostic imaging, image-guided therapy, patient monitoring, health informatics, and consumer health and home care products. Philips aims to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. Recognized for its commitment to sustainability and social responsibility, Philips has been named a top employer by Forbes and ranked as the highest medical technology company among Clarivate's Top 100 Global Innovators in 2025.
Developed with Dr. Justin Davies and powered by Cerebria, the adaptive platform delivers case-based, multilingual IVUS education worldwide, accelerating image interpretation skills and improving care outcomes.
Through Project SEARCH, Philips develops realistic algorithm-generated CT and MRI datasets that enhance AI accuracy, protect patient privacy, and build clinician trust across oncology and cardiovascular applications.
Partnership integrates connected Philips AEDs into Securitas’ guarding solutions, ensuring monitored devices, trained responders, and faster action during sudden cardiac arrests in workplaces and public areas.
Global adoption milestone highlights advanced imaging efficiency, supporting over 15 million patient treatments annually across 170+ countries since Zenition’s 2019 launch.
The collaboration integrates Masimo’s SET pulse oximetry, Radius PPG, wearable sensors, and AI-driven insights into Philips’ monitoring platforms, enhancing interoperability, mobility, and clinical decision-making efficiency.
The Philips pathology scanner is the first in the world to offer native DICOM JPEG XL output, which reduces file sizes by up to 50% while maintaining high image quality.
The latest enhancements to EPIQ CVx and Affiniti CVx introduce FDA-cleared 2D/3D imaging, AI-powered clinical applications, and intelligent automation, enabling faster, reproducible results to meet growing demands in cardiac care.
Philips UroNav receives FDA 510(k) clearance, advancing minimally invasive prostate cancer therapy with precise, image-guided navigation for personalized care.